Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CRISPR-Cas9
CRISPR-Cas9
That $335M JV Bayer set up on CRISPR/Cas9? They’re letting the biotech partner carry on
Endpoints
Mon, 10/21/19 - 04:34 pm
Bayer
CRISPR Therapeutics
CRISPR-Cas9
CRISPR hits a snag: Our immune systems may attack the treatment
Stat
Mon, 01/8/18 - 09:44 am
CRISPR
CRISPR-Cas9
Editas loses its lead in the biotech race to launch the first CRISPR/Cas9 human study
Endpoints
Tue, 05/16/17 - 11:35 am
Editas
CRISPR-Cas9
CRISPR Therapeutics
Intellia Therapeutics
Califf cautions against lowering FDA standards; Editas outlines $1B milestone package
Endpoints
Thu, 03/23/17 - 09:49 pm
Robert Califf
FDA
Editas
Allergan
CRISPR-Cas9
Allergan antes up $90M in a CRISPR/Cas9 collaboration with Editas on eye diseases
Endpoints
Tue, 03/14/17 - 09:42 am
Allergan
eye health
CRISPR-Cas9
Editas
A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD
Endpoints
Mon, 02/27/17 - 09:13 am
Duchenne Muscular Dystrophy
R&D
CRISPR-Cas9
Exonics Therapeutics
The CRISPR patent decision: Your six takeaways
Stat
Thu, 02/16/17 - 10:13 am
CRISPR Therapeutics
patents
CRISPR-Cas9
Broad Institute
CRISPR identifies genes that might be targeted to hobble HIV infection
Stat
Tue, 10/25/16 - 03:48 pm
CRISPR-Cas9
HIV
genome editing
Bayer, CRISPR christen Casebia
BioPharma Dive
Fri, 08/19/16 - 11:29 am
Bayer
CRISPR Therapeutics
Casebia Therapeutics
CRISPR-Cas9
Startup biotech Homology Med aims to 'leapfrog' CRISPR competitors
BioPharma Dive
Wed, 06/22/16 - 10:43 am
Homology Med
CRISPR
CRISPR-Cas9
gene editing
What's Up Next? Biotech And Pharma Predictions For 2016
Forbes
Fri, 01/1/16 - 01:04 pm
biotech
Martin Shkreli
Valeant Pharmaceuticals
drug pricing
Theranos
Obamacare
Pfizer
CRISPR-Cas9
Bill Gates And 13 Other Investors Pour $120 Million Into Revolutionary Gene-Editing Startup
Forbes
Mon, 08/10/15 - 08:03 am
Bill Gates
gene editing
CRISPR-Cas9
Editas Medicine
Juno Therapeutics